A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

NCT04622358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG: AD-214-02
DRUG: Rabeprazole

Sponsor

Addpharma Inc.